Amedisys, Inc. AMED

Set alert

Price alert · AMED

All alert types
100.99 0.00 0.00%

At close · Aug 14

100.93 Day range 101.02
82.15 52-week range 101.02
YTD
+11.23%
1 year
+3.24%
Open
101.00
Prev close
100.99
Mkt cap
3.32B
Vol
1.04M
Avg vol
780.22K
EPS
2.57
P/E
19.86
Div yield
0.00%
More statistics
Low
100.93
High
101.02
Forward P/E
19.76
Beta
0.90
Short ratio
6.84
Inst. own
96.37%
Dividend
0.00
Ex-div date
Earnings
Jul 29, 2025
50-d avg
98.01
200-d avg
93.25
1y target
0.00

6M chart

Chart tools
Interval

Events in this range
  • Feb 26, 2025Earnings: —; estimate 1.05; surprise —%
  • Mar 4, 2025Rating: Stephens & Co. · Equal-Weight → Equal-Weight
  • Apr 16, 2025Rating: RBC Capital · Outperform → Outperform
  • Apr 23, 2025Earnings: —; estimate 1.13; surprise —%
  • Jul 29, 2025Earnings: —; estimate 1.39; surprise —%
Signals (23)
NameDateAgo
RSI: OverboughtAug 7, 20251 year ago
MACD: Buy SignalJul 31, 20251 year ago
MACD: Sell SignalJul 1, 20251 year ago
RSI: OverboughtJun 30, 20251 year ago
RSI: OverboughtJun 25, 20251 year ago
RSI: OverboughtJun 23, 20251 year ago
RSI: OverboughtJun 12, 20251 year ago
MACD: Buy SignalJun 10, 20251 year ago
MACD: Sell SignalMay 13, 20251 year ago
RSI: OverboughtApr 24, 20251 year ago
SMA: BullishApr 22, 20251 year ago
MACD: Buy SignalApr 22, 20251 year ago
SMA: BearishApr 4, 20251 year ago
MACD: Sell SignalApr 4, 20251 year ago
MACD: Buy SignalApr 1, 20251 year ago
MACD: Sell SignalMar 31, 20251 year ago
MACD: Buy SignalMar 27, 20251 year ago
MACD: Sell SignalMar 26, 20251 year ago
MACD: Buy SignalMar 13, 20251 year ago
MACD: Sell SignalMar 10, 20251 year ago

Newest 20 of 23.

Analyst view

Consensus: hold

Hold
Price target (mean) —
Ratings (0m) 6 1 buy · 4 hold · 1 sell
  • Strong buy1
  • Buy0
  • Hold4
  • Sell1
  • Strong sell0

Recommendation trend

  • This month 6
  • 1 month ago 12
  • 2 months ago 12
  • 3 months ago 11

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

AMED analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter1.201.07 – 1.411.00+20.3%635.81M+8.2%6
Next quarter1.271.12 – 1.460.96+32.1%650.20M+8.7%5
Current year4.994.68 – 5.354.32+15.5%2.50B+6.3%11

Upgrades and downgrades

The latest rating changes

AMED analyst upgrades and downgrades
DateFirmActionFromTo
Apr 16, 2025RBC CapitalReiteratedOutperformOutperform
Mar 4, 2025Stephens & Co.ReiteratedEqual-WeightEqual-Weight
Feb 12, 2025Stephens & Co.ReiteratedEqual-WeightEqual-Weight
Jul 31, 2024Deutsche BankDowngradeBuyHold
Jul 25, 2024Cantor FitzgeraldReiteratedNeutralNeutral
Jul 1, 2024William BlairDowngradeOutperformMarket Perform
Apr 25, 2024Cantor FitzgeraldReiteratedNeutralNeutral
Mar 26, 2024Raymond JamesMaintainedMarket PerformMarket Perform
Mar 25, 2024RBC CapitalMaintainedOutperformOutperform
Sep 14, 2023Cantor FitzgeraldMaintainedNeutralNeutral
Jul 31, 2023TD CowenMaintainedMarket PerformMarket Perform
Jul 27, 2023Credit SuisseReiteratedNeutralNeutral
Jul 6, 2023JefferiesDowngradeBuyHold
Jun 28, 2023BenchmarkDowngradeBuyHold
Jun 27, 2023BenchmarkDowngradeBuyHold
Jun 27, 2023Truist SecuritiesMaintainedHoldHold
Jun 7, 2023Truist SecuritiesDowngradeBuyHold
Jun 6, 2023Cantor FitzgeraldMaintainedNeutralNeutral
Jun 6, 2023BenchmarkReiteratedBuyBuy
Jun 6, 2023Credit SuisseDowngradeOutperformNeutral
May 8, 2023TD CowenMaintained—Market Perform
May 5, 2023BarclaysMaintained—Equal-Weight
May 4, 2023Truist SecuritiesMaintained—Buy
May 4, 2023Stephens & Co.Reiterated—Equal-Weight
Apr 21, 2023Cantor FitzgeraldInitiated—Neutral
Apr 13, 2023Truist SecuritiesMaintained—Buy
Mar 14, 2023BenchmarkReiterated—Buy
Mar 14, 2023Stephens & Co.Reiterated—Equal-Weight
Mar 13, 2023BarclaysInitiated—Equal-Weight
Feb 27, 2023Credit SuisseReiterated—Outperform